Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Research & Development (2019 - 2025)

Revolution Medicines has reported Research & Development over the past 7 years, most recently at $294.9 million for Q4 2025.

  • Quarterly results put Research & Development at $294.9 million for Q4 2025, up 56.8% from a year ago — trailing twelve months through Dec 2025 was $987.3 million (up 66.55% YoY), and the annual figure for FY2025 was $987.3 million, up 66.72%.
  • Research & Development for Q4 2025 was $294.9 million at Revolution Medicines, up from $262.5 million in the prior quarter.
  • Over the last five years, Research & Development for RVMD hit a ceiling of $294.9 million in Q4 2025 and a floor of $40.9 million in Q1 2021.
  • Median Research & Development over the past 5 years was $102.9 million (2023), compared with a mean of $122.2 million.
  • Peak annual rise in Research & Development hit 124.54% in 2023, while the deepest fall reached 22.05% in 2023.
  • Revolution Medicines' Research & Development stood at $53.7 million in 2021, then grew by 23.19% to $66.1 million in 2022, then surged by 124.54% to $148.5 million in 2023, then rose by 26.68% to $188.1 million in 2024, then skyrocketed by 56.8% to $294.9 million in 2025.
  • The last three reported values for Research & Development were $294.9 million (Q4 2025), $262.5 million (Q3 2025), and $224.1 million (Q2 2025) per Business Quant data.